Holen Sie sich die Stockscreener-App
16.62
0.18%
0.03
Handel nachbörslich:
16.66
0.04
+0.24%
Schlusskurs vom Vortag:
$16.59
Offen:
$16.19
24-Stunden-Volumen:
639.71K
Relative Volume:
0.62
Marktkapitalisierung:
$1.81B
Einnahmen:
$525.66M
Nettoeinkommen (Verlust:
$-192.74M
KGV:
-8.9355
EPS:
-1.86
Netto-Cashflow:
$-120.97M
1W Leistung:
-1.60%
1M Leistung:
+12.91%
6M Leistung:
+12.45%
1J Leistung:
+20.61%
1-Tages-Spanne:
$15.89
$16.97
1-Wochen-Bereich:
$15.10
$17.69
52-Wochen-Spanne:
$10.87
$24.73
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
Novocure's COO Mukund sells shares worth $2,540 - Investing.com
Novocure's oncology president sells $9,530 in shares - Investing.com
Michal Nath Puri Sells 810 Shares of NovoCure Limited (NASDAQ:NVCR) Stock - MarketBeat
Novocure's oncology president sells $9,530 in shares By Investing.com - Investing.com Australia
Novocure's COO Mukund sells shares worth $2,540 By Investing.com - Investing.com Australia
NovoCure Ltd (NVCR) Shares Up 3.96% on Nov 4 - GuruFocus.com
FY2024 EPS Estimates for NovoCure Raised by HC Wainwright - MarketBeat
Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report - Simply Wall St
NovoCure Limited (NASDAQ:NVCR) Q3 2024 Earnings Call Transcript - Insider Monkey
NovoCure shares hold Buy rating, steady price target post-earnings - Investing.com
NovoCure shares hold Buy rating, steady price target post-earnings By Investing.com - Investing.com UK
NovoCure's (NVCR) Buy Rating Reiterated at HC Wainwright - MarketBeat
NovoCure’s Strong Q3 and Leadership Changes in 2024 - Yahoo Finance
NovoCure: Q3 Earnings Snapshot - Milford Mirror
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - Yahoo Finance
Novocure names Christoph Brackmann as new CFO - Investing.com India
Novocure’s Q3 2024 Results Highlight Growth and Innovation - TipRanks
NovoCure (NASDAQ:NVCR) Stock Price Down 7.1%Should You Sell? - MarketBeat
Novocure Ltd earnings beat by $0.05, revenue topped estimates - Investing.com
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Novocure Appoints Christoph Brackmann as Chief Financial Officer - Yahoo Finance
Novocure Reports Third Quarter 2024 Financial Results - Yahoo Finance
Semanteon Capital Management LP Makes New Investment in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Shares Sold by SG Americas Securities LLC - MarketBeat
Novocure shares soar 33% as FDA approves lung cancer treatment - MSN
Leerink Partnrs Forecasts Stronger Earnings for NovoCure - MarketBeat
NovoCure scoops FDA approval on wearable for metastatic cancer treatment - Medical Device Network
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment - Yahoo Finance
Novocure scoops FDA approval for electric field lung cancer treatment device - Mugglehead
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings) - Benzinga
NovoCure Ltd (NVCR) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
NovoCure (NASDAQ:NVCR) Shares Gap UpTime to Buy? - MarketBeat
Novocure wins FDA approval for electric field device in lung cancer - BioPharma Dive
A new trading data show NovoCure Ltd (NVCR) is showing positive returns. - SETE News
NovoCure Ltd (NVCR)’s Market Momentum: Closing Strong at 17.78, Up 10.71 - The Dwinnex
NovoCure: There Is Still More Upside (Rating Upgrade) (NASDAQ:NVCR) - Seeking Alpha
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class ActionNVCR - AsiaOne
NovoCure stock upgraded to buy, price target set on recent FDA approval - Investing.com
NovoCure stock upgraded to buy, price target set on recent FDA approval By Investing.com - Investing.com South Africa
NovoCure (NASDAQ:NVCR) Rating Increased to Buy at HC Wainwright - MarketBeat
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients - Yahoo Finance
Novocure shares soar 33% as FDA approves lung cancer treatment By Investing.com - Investing.com South Africa
Novocure jumps on FDA approval for lung cancer treatment - XM
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? - Yahoo Finance
NovoCure Breaks Above 200-Day Moving AverageBullish for NVCR - Nasdaq
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer - Yahoo Finance
After-hours movers: United Airlines, Interactive Brokers, J.B. Hunt and more - StreetInsider.com
How did NovoCure Ltd (NVCR) fare last session? - US Post News
The time has not yet come to remove your chips from the table: NovoCure Ltd (NVCR) - SETE News
NovoCure Ltd (NVCR) shows promising results - US Post News
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novocure Ltd-Aktie (NVCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Nov 01 '24 |
Sale |
15.94 |
598 |
9,531 |
161,236 |
| Paravasthu Mukund | Chief Operating Officer |
Nov 01 '24 |
Sale |
15.88 |
160 |
2,540 |
3,503 |
| Cordova Ashley | Chief Financial Officer |
Aug 02 '24 |
Sale |
20.14 |
688 |
13,857 |
219,179 |
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer |
Jun 05 '24 |
Option Exercise |
22.82 |
124,373 |
2,838,192 |
124,373 |
| VERNON W ANTHONY | Director |
Jun 04 '24 |
Sale |
23.89 |
964 |
23,033 |
164,833 |
| Scannell Timothy J | Director |
Jun 04 '24 |
Sale |
23.89 |
964 |
23,027 |
2,964 |
| LEUNG GABRIEL | Director |
Jun 04 '24 |
Sale |
23.89 |
964 |
23,025 |
78,175 |
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer |
Mar 01 '24 |
Sale |
16.03 |
2,107 |
33,769 |
252,452 |
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer |
Mar 04 '24 |
Sale |
16.01 |
1,217 |
19,484 |
251,235 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Mar 01 '24 |
Sale |
16.03 |
1,679 |
26,909 |
160,938 |
0.47%
1.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):